T1	PROC 1 20	Estudio comparativo
#1	AnnotatorNotes T1	C1579762; comparative study research; Research Activity
T2	PROC 27 63	erradicación del Helicobacter pylori
#2	AnnotatorNotes T2	C0559761; Helicobacter eradication therapy; Therapeutic or Preventive Procedure
T3	CHEM 65 91	ranitidina-citrato bismuto
#3	AnnotatorNotes T3	C0139919; ranitidine bismuth citrate;  Organic Chemical · Pharmacologic Substance
T5	PROC 158 178	Comparar la eficacia
#5	AnnotatorNotes T5	C1707887; Efficacy Study; Research Activity
T6	CHEM 99 108	omeprazol
#6	AnnotatorNotes T6	C0028978; omeprazole; Organic Chemical · Pharmacologic Substance
T7	PROC 185 221	erradicación del Helicobacter pylori
#7	AnnotatorNotes T7	C0559761; Helicobacter eradication therapy; Therapeutic or Preventive Procedure
T8	CHEM 226 252	ranitidina-citrato bismuto
#8	AnnotatorNotes T8	C0139919; ranitidine bismuth citrate;  Organic Chemical · Pharmacologic Substance
T10	PROC 268 279	tratamiento
#10	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	CHEM 292 301	omeprazol
#11	AnnotatorNotes T11	C0028978; omeprazole; Organic Chemical · Pharmacologic Substance
T12	PROC 388 400	erradicación
#12	AnnotatorNotes T12	C3178994; Disease Eradication; Health Care Activity
T13	CHEM 462 465	OCA
#13	AnnotatorNotes T13	C0002645; amoxicillin; Organic Chemical · Antibiotic + C0028978; omeprazole; Organic Chemical · Pharmacologic Substance + C0055856; clarithromycin; Organic Chemical · Antibiotic
T14	PROC 439 460	pautas de tratamiento
#14	AnnotatorNotes T14	C0935576; treatment guideline; Therapeutic or Preventive Procedure
T15	CHEM 469 478	omeprazol
#15	AnnotatorNotes T15	C0028978; omeprazole; Organic Chemical · Pharmacologic Substance
T16	CHEM 495 506	amoxicilina
#16	AnnotatorNotes T16	C0002645; amoxicillin; Organic Chemical · Antibiotic
T17	CHEM 520 534	claritromicina
#17	AnnotatorNotes T17	C0055856; clarithromycin; Organic Chemical · Antibiotic
T18	CHEM 597 608	amoxicilina
#18	AnnotatorNotes T18	C0002645; amoxicillin; Organic Chemical · Antibiotic
T19	CHEM 622 636	claritromicina
#19	AnnotatorNotes T19	C0055856; clarithromycin; Organic Chemical · Antibiotic
T20	PROC 673 685	erradicación
#20	AnnotatorNotes T20	C3178994; Disease Eradication; Health Care Activity
T21	PROC 703 719	test del aliento
#21	AnnotatorNotes T21	C0006153; Breath Tests; Diagnostic Procedure
T22	PROC 755 766	tratamiento
#22	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 982 994	erradicación
#23	AnnotatorNotes T23	C3178994; Disease Eradication; Health Care Activity
T24	PROC 1087 1099	erradicación
#24	AnnotatorNotes T24	C3178994; Disease Eradication; Health Care Activity
T25	PROC 1104 1113	protocolo
#25	AnnotatorNotes T25	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T26	DISO 1253 1272	efectos secundarios
#26	AnnotatorNotes T26	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T27	PROC 1293 1320	suspendieron el tratamiento
#27	AnnotatorNotes T27	C0850893; stop medication; Therapeutic or Preventive Procedure
T28	CHEM 1349 1375	Ranitidina citrato bismuto
#28	AnnotatorNotes T28	C0139919; ranitidine bismuth citrate;  Organic Chemical · Pharmacologic Substance
T30	PROC 1428 1439	tratamiento
#30	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	CHEM 1452 1461	omeprazol
#31	AnnotatorNotes T31	C0028978; omeprazole; Organic Chemical · Pharmacologic Substance
T32	PROC 1468 1504	erradicación del Helicobacter pylori
#32	AnnotatorNotes T32	C0559761; Helicobacter eradication therapy; Therapeutic or Preventive Procedure
T33	CHEM 117 129	antibióticos
#33	AnnotatorNotes T33	C0003232; Antibiotics; Antibiotic
T34	PROC 872 884	randomizados
#34	AnnotatorNotes T34	C0034656; Randomization; Research Activity
T35	DISO 1325 1332	diarrea
#35	AnnotatorNotes T35	C0011991; Diarrhea; Sign or Symptom
T36	CHEM 1384 1396	antibióticos
#36	AnnotatorNotes T36	C0003232; Antibiotics; Antibiotic
T37	PROC 324 384	Se estudiaron de forma prospectiva y randomizada la eficacia
#37	AnnotatorNotes T37	C1707887; Efficacy Study; Research Activity + C0033522; Prospective Studies; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
T38	CHEM 887 890	OCA
#38	AnnotatorNotes T38	C0002645; amoxicillin; Organic Chemical · Antibiotic + C0028978; omeprazole; Organic Chemical · Pharmacologic Substance + C0055856; clarithromycin; Organic Chemical · Antibiotic
T39	CHEM 1030 1033	OCA
#39	AnnotatorNotes T39	C0002645; amoxicillin; Organic Chemical · Antibiotic + C0028978; omeprazole; Organic Chemical · Pharmacologic Substance + C0055856; clarithromycin; Organic Chemical · Antibiotic
T40	CHEM 1126 1129	OCA
#40	AnnotatorNotes T40	C0002645; amoxicillin; Organic Chemical · Antibiotic + C0028978; omeprazole; Organic Chemical · Pharmacologic Substance + C0055856; clarithromycin; Organic Chemical · Antibiotic
T41	CHEM 1206 1209	OCA
#41	AnnotatorNotes T41	C0002645; amoxicillin; Organic Chemical · Antibiotic + C0028978; omeprazole; Organic Chemical · Pharmacologic Substance + C0055856; clarithromycin; Organic Chemical · Antibiotic
T42	LIVB 44 63	Helicobacter pylori
#42	AnnotatorNotes T42	C0079488; Helicobacter pylori; Bacterium
T43	Duration 138 144	7 días
T44	LIVB 202 221	Helicobacter pylori
#43	AnnotatorNotes T44	C0079488; Helicobacter pylori; Bacterium
T45	LIVB 408 417	pacientes
#44	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	Dose 479 484	20 mg
T47	Dose 535 541	500 mg
T48	Duration 559 565	7 días
T49	Dose 580 586	400 mg
T50	Dose 637 643	500 mg
T51	Duration 661 667	7 días
T52	Duration 720 738	al menos 4 semanas
T53	LIVB 785 792	hombres
#45	AnnotatorNotes T53	C0025266; Male population group; Population Group
T54	LIVB 798 805	mujeres
#46	AnnotatorNotes T54	C0043210; Woman; Population Group
T55	Age 831 838	48 años
T56	Age 840 850	18-82 años
T57	LIVB 857 866	pacientes
#47	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	LIVB 899 908	pacientes
#48	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 932 941	pacientes
#49	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1186 1195	pacientes
#50	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	LIVB 1216 1225	pacientes
#51	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 1485 1504	Helicobacter pylori
#52	AnnotatorNotes T62	C0079488; Helicobacter pylori; Bacterium
T63	Frequency 484 493	/12 horas
T64	Dose 507 509	1g
T65	Frequency 509 518	/12 horas
T66	Frequency 541 550	/12 horas
T67	Frequency 643 652	/12 horas
T68	Frequency 611 620	/12 horas
T69	Dose 609 611	1g
T70	Frequency 586 595	/12 horas
R2	Used_for Arg1:T3 Arg2:T2	
R3	Combined_with Arg1:T6 Arg2:T33	
T71	Quantifier_or_Qualifier 113 116	dos
R4	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T71	
R5	Has_Duration_or_Interval Arg1:T6 Arg2:T43	
R6	Has_Duration_or_Interval Arg1:T33 Arg2:T43	
R8	Has_Duration_or_Interval Arg1:T3 Arg2:T43	
R10	Used_for Arg1:T11 Arg2:T10	
R11	Used_for Arg1:T8 Arg2:T7	
R12	Used_for Arg1:T11 Arg2:T7	
R13	Experiences Arg1:T45 Arg2:T12	
R14	Experiences Arg1:T45 Arg2:T14	
R15	Experiences Arg1:T45 Arg2:T13	
R16	Experiences Arg1:T45 Arg2:T15	
R17	Experiences Arg1:T45 Arg2:T16	
R18	Has_Dose_or_Strength Arg1:T15 Arg2:T46	
R19	Has_Frequency Arg1:T15 Arg2:T63	
R20	Has_Frequency Arg1:T16 Arg2:T65	
R21	Has_Dose_or_Strength Arg1:T16 Arg2:T64	
R22	Has_Dose_or_Strength Arg1:T17 Arg2:T47	
R23	Has_Frequency Arg1:T17 Arg2:T66	
R24	Has_Duration_or_Interval Arg1:T17 Arg2:T48	
R25	Has_Duration_or_Interval Arg1:T13 Arg2:T48	
R26	Has_Duration_or_Interval Arg1:T15 Arg2:T48	
R27	Has_Duration_or_Interval Arg1:T16 Arg2:T48	
R29	Combined_with Arg1:T15 Arg2:T16	
R30	Combined_with Arg1:T16 Arg2:T17	
R31	Experiences Arg1:T45 Arg2:T17	
R32	Combined_with Arg1:T18 Arg2:T19	
R35	Has_Dose_or_Strength Arg1:T18 Arg2:T69	
R36	Has_Dose_or_Strength Arg1:T19 Arg2:T50	
R37	Has_Frequency Arg1:T19 Arg2:T67	
R38	Has_Duration_or_Interval Arg1:T19 Arg2:T51	
R40	Overlap Arg1:T21 Arg2:T52	
R42	Before Arg1:T22 Arg2:T21	
R44	Has_Age Arg1:T54 Arg2:T55	
R45	Has_Age Arg1:T53 Arg2:T55	
R46	Has_Age Arg1:T53 Arg2:T56	
R47	Has_Age Arg1:T54 Arg2:T56	
R48	Experiences Arg1:T57 Arg2:T38	
R49	Before Arg1:T34 Arg2:T38	
T72	Observation 942 969	completaban todo el estudio
#53	AnnotatorNotes T72	C2732579; Completion of clinical trial; Finding
T73	CONC 999 1017	intención a tratar
#54	AnnotatorNotes T73	C1292734; Treatment intent; Functional Concept
R51	Used_for Arg1:T73 Arg2:T23	
R52	Used_for Arg1:T39 Arg2:T23	
R53	Used_for Arg1:T40 Arg2:T24	
R54	Used_for Arg1:T40 Arg2:T25	
R55	Experiences Arg1:T60 Arg2:T41	
R56	Experiences Arg1:T60 Arg2:T26	
R57	Experiences Arg1:T61 Arg2:T26	
R58	Experiences Arg1:T61 Arg2:T27	
R60	Experiences Arg1:T61 Arg2:T35	
R63	Used_for Arg1:T31 Arg2:T30	
R64	Used_for Arg1:T28 Arg2:T30	
R65	Overlap Arg1:T30 Arg2:T32	
R28	Has_Frequency Arg1:T18 Arg2:T68	
T74	CHEM 577 579	RB
R33	Has_Dose_or_Strength Arg1:T74 Arg2:T49	
R34	Has_Frequency Arg1:T74 Arg2:T70	
R61	Combined_with Arg1:T28 Arg2:T36	
#29	AnnotatorNotes T74	C0139919; ranitidine bismuth citrate;  Organic Chemical · Pharmacologic Substance
T9	CHEM 254 256	RB
#9	AnnotatorNotes T9	C0139919; ranitidine bismuth citrate;  Organic Chemical · Pharmacologic Substance
R9	Used_for Arg1:T9 Arg2:T7	
R1	Used_for Arg1:T13 Arg2:T14	
R7	Used_for Arg1:T15 Arg2:T14	
R62	Used_for Arg1:T74 Arg2:T14	
R66	Combined_with Arg1:T74 Arg2:T18	
#4	AnnotatorNotes T71	C0205448; Two; Quantitative Concept
T4	Quantifier_or_Qualifier 1380 1383	dos
#55	AnnotatorNotes T4	C0205448; Two; Quantitative Concept
R39	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T4	
A1	Experiencer T60 Patient
A2	Experiencer T61 Patient
A3	Experiencer T45 Patient
A4	Experiencer T53 Patient
A5	Experiencer T54 Patient
A6	Experiencer T57 Patient
A7	Experiencer T59 Patient
A8	Experiencer T58 Patient
